BioSpace News Archive

Hummingbird Bioscience announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a unique anti-VISTA antibody developed using Hummingbird’s Rational Antibody Discovery platform to address VISTA-mediated suppression of anti-tumor immune responses, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer.

Inventprise, a biotechnology company specializing in novel, affordable and highly impactful vaccines, announced that the Bill & Melinda Gates Foundation, a global non-profit organization, has made a program-related investment in the company’s continued development of IVT-25, an investigational pneumococcal conjugate vaccine designed to prevent pneumococcal bacterial infections.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the quarter ended September 30, 2021, and provided an update on clinical and corporate progress.

KalVista Pharmaceuticals, Inc. today provided an update on the clinical trial progress for KVD900 in development for oral on-demand treatment of hereditary angioedema (HAE).

Perrigo Company plc today announced financial results for the third quarter of fiscal year 2021 ended October 2, 2021. All comparisons are against the prior year fiscal third quarter, unless otherwise noted.

TCR 2 Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Zain Kassam, MD, MPH has elected to step down as Chief Medical Officer in order to return to Canada to attend to a family health matter.

Immunocore Holdings plc, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, announced its financial results for the quarter and nine months ended September 30, 2021 and provides a business update.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that data from the Phase 3 DERBY and OAKS studies will be presented as part of three oral presentations at the American Academy of Ophthalmology Annual Meeting to be held November 12 – 15, 2021 in New Orleans, Louisiana.